Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study

American Journal of Obstetrics and Gynecology
Fulvia ManciniCesare Battaglia

Abstract

We sought to verify if an oral contraceptive (OC) containing drospirenone affects the cardiovascular risk of patients with polycystic ovary syndrome (PCOS). A total of 28 women with PCOS (16 lean [group A] and 12 overweight [group B]) were assessed at baseline and after 6 months therapy with an OC. Leptin, homocysteine, endothelin-1, and flow-mediated dilatation of brachial artery were measured. The brachial artery diameter and the pulsatility index, after the reactive hyperemia, did not change in group A; it improved significantly in group B after 6 months of treatment. At baseline and after therapy the plasma levels of homocysteine and endothelin-1 did not differ among the groups. Leptin was significantly lower at baseline in group A compared to group B. The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS.

References

Sep 1, 1989·Trends in Pharmacological Sciences·M Yanagisawa, T Masaki
Apr 16, 1998·The New England Journal of Medicine·G N Welch, J Loscalzo
Sep 2, 1999·Advances in Enzyme Regulation·J D HouseJ T Brosnan
Oct 16, 2001·The Journal of Clinical Endocrinology and Metabolism·E Diamanti-KandarakisI Migdalis
Jul 24, 2002·Clinical Biochemistry·Javier Gómez-AmbrosiGema Frühbeck
Aug 30, 2002·Metabolism: Clinical and Experimental·Gabriele S Merki-FeldPaul J Keller
Feb 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Francesco OrioGaetano Lombardi
Dec 23, 2003·Human Reproduction·UNKNOWN Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·N BoulmanZ Blumenfeld
Jul 28, 2005·The Journal of Clinical Endocrinology and Metabolism·C MeyerH J Teede
Oct 6, 2005·Climacteric : the Journal of the International Menopause Society·J-M Foidart
Jun 19, 2007·Drugs & Aging·Madhavi MallareddyWilliam B White
Feb 2, 2008·Obstetrics and Gynecology·Cesare BattagliaDomenico de Aloysio

❮ Previous
Next ❯

Citations

Jul 10, 2013·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Zeinab HeidarzadehFarzad Fatehi
Aug 21, 2012·Nursing for Women's Health·Jessica Watkins Smith, Julie Smith Taylor
Jun 19, 2012·Clinical Endocrinology·Ayla HarmanciBulent Okan Yildiz
Jul 29, 2011·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Elena E Grodnitskaya, Mark A Kurtser
Feb 15, 2012·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Polyana S MaierPoli M Spritzer
May 23, 2015·Expert Opinion on Pharmacotherapy·Morena Luigia RoccaMichele Morelli
Nov 19, 2011·European Journal of Endocrinology·T Sathyapalan, S L Atkin
Jan 1, 2019·International Journal of Inflammation·Sebastião Freitas de MedeirosMárcia Marly Winck Yamamoto
Jul 9, 2020·Therapeutic Advances in Endocrinology and Metabolism·Punith KempegowdaMichael W O'Reilly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.